News - EGFR exon 20 insertion

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. (PubMed, Virchows Arch)

RICTOR mutations were associated with a high-risk subset of EGFR-mutant metastatic lung adenocarcinoma characterized by more aggressive clinical features and worse survival. These findings suggest the need for prospective validation and support the potential integration of RICTOR status into molecular risk stratification frameworks for precision oncology.

3 days ago

Retrospective data • Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

BRAF V600E • EGFR mutation • KRAS G12C • EGFR exon 19 deletion • EGFR exon 20 insertion • KRAS G12

TruSight Oncology 500 Assay

Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab. (PubMed, J Clin Med)

Ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has shown a survival benefit when combined with docetaxel in patients with previously treated advanced NSCLC. Collectively, these agents highlight the expanding role of antibody-based therapies in NSCLC and underscore the importance of biomarker-driven patient selection and treatment personalization. Ongoing research into resistance mechanisms, predictive biomarkers, and combination approaches is expected to further refine the integration of antibody-based strategies in precision oncology for NSCLC.

3 days ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KDR (Kinase insert domain receptor)

EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation

Tecentriq (atezolizumab) • docetaxel • Cyramza (ramucirumab)

Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation. (PubMed, Bioorg Med Chem)

The C797S mutation in the epidermal growth factor receptor (EGFR) presents a significant challenge in treating non-small cell lung cancer (NSCLC), as it confers resistance to osimertinib...In vivo antitumor activity studies demonstrated that LN-B72 significantly inhibited tumor growth. This work establishes a promising foundation for developing novel therapeutic strategies targeting NSCLC patients with the C797S mutation.

4 days ago

Preclinical • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion

Tagrisso (osimertinib)

OMAE: Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)

P=N/A, N=100, Recruiting, GFPC Investigation

6 days ago

New trial

EGFR (Epidermal growth factor receptor)

EGFR exon 20 insertion • EGFR exon 20 mutation

Tagrisso (osimertinib)

10d

Whole exome sequencing of lung cancer in Indian patients reveals driver genes and novel mutations with therapeutic potential. (PubMed, Indian J Surg Oncol)

These findings underscore the value of WES in uncovering clinically relevant mutations and support the integration of genomic profiling into precision oncology strategies for Indian lung cancer patients. The online version contains supplementary material available at 10.1007/s13193-025-02359-9.

10 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • MUC16 (Mucin 16, Cell Surface Associated) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • ARID2 (AT-Rich Interaction Domain 2) • FAT4 (FAT Atypical Cadherin 4) • MUC4 (Mucin 4, Cell Surface Associated) • UBXN11 (UBX Domain Protein 11) • CDC27 (Cell Division Cycle 27)

TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation

13d

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC (clinicaltrials.gov)

P1, N=76, Recruiting, ORIC Pharmaceuticals | Trial completion date: May 2027 --> Dec 2027 | Trial primary completion date: May 2026 --> Dec 2026

13 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation

enozertinib (ORIC-114) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

17d

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting

17 days ago

Enrollment open

MET (MET proto-oncogene, receptor tyrosine kinase)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation

CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay

Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)

19d

Acquired CD74-ROS1 fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report. (PubMed, J Chemother)

The combination of osimertinib and crizotinib resulted in a marked clinical and metabolic response, was well tolerated, and the patient remained in remission. This rare case highlights that acquired CD74-ROS1 fusions may contribute to osimertinib resistance and suggests that combination targeted therapy may represent a potential therapeutic approach in selected patients.

19 days ago

Journal

EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD74 (CD74 Molecule)

EGFR mutation • EGFR T790M • EGFR exon 20 insertion • ROS1 fusion • EGFR exon 20 mutation

Xalkori (crizotinib) • Tagrisso (osimertinib)

22d

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov)

P1, N=56, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2026 --> Jan 2028

22 days ago

Trial primary completion date

STK11 (Serine/threonine kinase 11)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation

Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)

24d

Clinical outcomes of a quadruplet regimen (immunotherapy, chemotherapy, anti-angiogenic therapy) in non-small cell lung cancer with EGFR exon 20 insertion mutations: a case series. (PubMed, AME Case Rep)

All were grade one to two, with no discontinuations due to toxicity. This small case series describes preliminary antitumor activity and a manageable safety profile with the quadruplet regimen in EGFR ex20ins-mutated NSCLC, warranting further investigation.

24 days ago

Clinical data • Journal • IO biomarker

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation